Circulating Tumor DNA-Guided Adjuvant and Post-Adjuvant Therapy in Resected Colorectal Cancer: From Molecular Residual Disease Detection to Proven Clinical Utility
Thai Hau Koo, Rishi Chowdhary, Kirti Arora, Kelly Chun Lynn Lai, Andee Dzulkarnaen Zakaria · 2026
Read Circulating Tumor DNA-Guided Adjuvant and Post-Adjuvant Therapy in Resected Colorectal Cancer: From Molecular Residual Disease Detection to Proven Clinical Utility by Thai Hau Koo, Rishi Chowdhary, Kirti Arora, Kelly Chun Lynn Lai, Andee Dzulkarnaen Zakaria (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13509608.txt.
Description
Thai Hau Koo, Rishi Chowdhary, Kirti Arora, Kelly Chun Lynn Lai, and Andee Dzulkarnaen Zakaria review blood tests for leftover cancer DNA after colon or rectal cancer surgery, in 2026 work. Fragments of tumor DNA in the blood clear within hours after full removal, so any signal found later points to tiny amounts of disease that scans cannot see. The review traces the field from early watching studies to recent large trials.
One major trial showed that test-guided care cut chemotherapy use in stage two colon cancer while survival without return of disease stayed equal. Other large trials found that stronger chemotherapy for test-positive patients did not improve outcomes, and one drug given at the first blood signal also fell short. The authors conclude the test predicts risk well, yet proof that acting on it helps patients is still catching up.
Catalog record
| CREATOR | Thai Hau Koo, Rishi Chowdhary, Kirti Arora, Kelly Chun Lynn Lai, Andee Dzulkarnaen Zakaria |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |